Burzynski Research Institute INC

Burzynski Research Institute, Inc. announced the resignation of its CFO and Secretary, Patryk P. Goscianski, effective April 17, 2026, with Dr. Stanislaw R. Burzynski assuming these roles without additional compensation.

Burzynski Research Institute, Inc. announced the appointment of M&K CPAs PLLC as its new independent registered public accounting firm following the resignation of PKF due to an acquisition.

Burzynski Research Institute, Inc. reported the resignation of its independent registered public accounting firm, Pannell Kerr Forster of Texas, P.C., effective July 21, 2025, due to PKF's recent acquisition by another firm.

Burzynski Research Institute continues to report net losses and a significant accumulated deficit, remaining dependent on Dr. Burzynski's funding while its Antineoplaston clinical trials remain under full FDA clinical hold.

Burzynski Research Institute reports continued net losses and a significant working capital deficit for Q2 2025, with its clinical trials remaining under full FDA clinical hold.

Burzynski Research Institute, Inc. filed its quarterly report, revealing ongoing net losses, a significant accumulated deficit, and continued reliance on its founder for funding, while its Antineoplaston drug trials remain under a full FDA clinical hold.

Burzynski Research Institute's Q3 2024 financial results reveal a net loss, with research and development expenses increasing and a clinical hold still in effect.

Burzynski Research Institute's latest quarterly report reveals increased operating losses and continued reliance on funding from Dr. Burzynski, while clinical trials remain on hold.

Burzynski Research Institute reported a net loss of $371,332 for the first quarter of 2024, with operations primarily funded by Dr. Burzynski's contributions.

Burzynski Research Institute reports its fiscal year 2025 results, highlighting ongoing research and development efforts despite a full clinical hold on its IND 43742.

Burzynski Research Institute's annual report reveals ongoing research and development efforts, funded by its majority shareholder, while facing a full clinical hold on its key drug trials.